LDHC

Across TCGA pan-cancer cohorts, LDHC Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LDHC data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LDHC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LDHC expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUSC, LGG, and UCEC are the cancer types where LDHC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.217	0.765	<.001	14	view →
LGG	OS	Median	All	0.021	0.896	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.513	0.871	.016	3	view →
LUAD	OS	Median	II,III,IV	1.000	0.220	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LDHC–LUSC (OS)

Open the LUSC breakdown →